Signios Biosciences
Private Company
Funding information not available
Overview
Signios Biosciences, founded in 2020 and rebranded from MedGenome US, is a genomics and proteomics contract research organization (CRO) providing comprehensive, scientist-led multiomics services. The company leverages a certified technology platform (Illumina, 10x Genomics, PacBio, Olink, Twist) and an in-house wet-lab and bioinformatics team to deliver services ranging from whole genome sequencing to spatial transcriptomics and antibody engineering. It supports research across oncology, immunology, rare diseases, neurology, and population health, aiming to accelerate biomarker discovery and therapeutic development for its partners.
Technology Platform
Integrated multiomics service platform utilizing certified third-party technologies (Illumina, 10x Genomics, PacBio, Olink, Twist) for NGS, single-cell, spatial, proteomics, and long-read sequencing, coupled with in-house bioinformatics pipelines and a scientist-led consultative model.
Opportunities
Risk Factors
Competitive Landscape
Signios competes in a crowded genomics CRO market against large, diversified CROs (e.g., LabCorp, IQVIA), large-scale pure-play sequencing service providers (e.g., Novogene, BGI), and niche bioinformatics firms. Differentiation is based on integrated multiomics, scientific consultation, and a fully in-house, quality-controlled workflow.